Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AIKLC3
- Target
- AIKLC3
01
Overview
The term "AIKLC3" does not correspond to a recognized therapeutic target, protein, or receptor in current scientific literature or pharmacological databases. It appears to be an incorrect or non-standard identifier. While "AIK" is an established alias for Aurora Kinase A (AURKA) and "LC3" refers to Microtubule-associated protein 1 light chain 3 (MAP1LC3), a key marker of autophagy, there is no documented target or molecule known as "AIKLC3." Research has shown that Aurora Kinase A can interact with MAP1LC3 to regulate mitophagy, but this interaction is described using the standard names of the individual proteins rather than a combined acronym. Consequently, no specific drugs, mechanisms of action, or disease roles can be attributed to "AIKLC3."
Beyond the preview
Go deeper on AIKLC3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIKLC3.